Trial Profile
A Randomised, Open Label, Multi-centre, Phase III Study to Investigate the Efficacy of Bendamustine Compared to Treatment of Physician's Choice in the Treatment of Subjects With Indolent Non-Hodgkin's Lymphoma (NHL) Refractory to Rituximab
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms ROBIN
- Sponsors Mundipharma International
- 05 Oct 2021 This trial has been completed in Spain (End Date: 31 Jul 2018), according to European Clinical Trials Database record.
- 30 Aug 2018 Status changed from recruiting to discontinued.
- 21 Aug 2018 This study has been discontinued in Slovakia.